A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

Inclusion Criteria: * Male and female outpatients 18 years of age and older * Patients with antihypertensive agents at screening: DBP\<110mmHg or Patients without antihypertensive agents at screening: DBP 90mmHg\~120mmHg * Subjects who agree to participate in this sudy and give written informed consent * Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study * Patients with not controlled blood pressure at baseline visit, by fimasartan 60mg 4weeks treatment, DBP 90mmHg\~109mmHg and SBP\<180mmHg Exclusion Criteria: * The sitting DBP is more than 120mmHg or severe hypertensive patient with sitting systolic blood pressure over 200mmHg Patients with secondary hypertension * Patients who are measured the mean difference of mean blood pressure under SiDBP 10mmHg or SiSBP 20mmHg at screening or baseline visit * Patients with severe renal(Creatinine more 1.5 times than upper limit of normal), gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit of normal)disease etc. which might affect absorption, disposition, metabolism or excretion of the drug * Patients with postural hypotension * Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes mellitus(HbA1c\>9%, regimen change of oral hypoglycemic agents within 12weeks, treated insulin before screening) * Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months * Patients with consumptive disease, autoimmune disease, connective tissue disease * Patients with a history of type B or C hepatitis(include carrier) * Patients with HIV or hepatitis * Patients with clinically significant laboratory abnormality * Patients receiving any drugs known to affect blood pressure or medical treatments that can influence the blood pressure * Patients with allergy or contraindication to any angiotensin II receptor antagonists * Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal * Patients judged to have a history of alcohol or drug abuse by the investigator * Patients participated other clinical trial 12 weeks before Screening - Patients judged to be inappropriate for this study by the investigator with other reasons